Market Overview

Nektar Up 3% Since 10 a.m. Release On Presentation Of Preclinical Comments For NKTR-181 This Week; Mizuho Analyst, Asked If Release Could Have Moved Stock, Said 'NKTR-181 accounts for $2-3/share in my valuation, so I don't think it can move the stock'

Share:

This headline-only article is meant to show you why a stock is moving, the most difficult aspect of stock trading. Every day we publish hundreds of headlines on any catalyst that could move the stocks you care about on Benzinga Pro, our flagship platform for fast, actionable information that promotes faster, smarter trading.

Benzinga Pro has an intuitively designed workspace that delivers powerful market insight, and is the solution of choice for thousands of professional and retail traders across the world.

Stop Googling for information and check out Benzinga Pro. You will never again be left in the dark on when a stock moves. You’ll have what you need to act in real-time — before the crowd.

Start your FREE 14-day trial of Benzinga Pro today.

Latest Ratings for NKTR

DateFirmActionFromTo
Jun 2018H.C. WainwrightDowngradesBuyNeutral
Jun 2018JP MorganMaintainsOverweightOverweight
Apr 2018Seaport GlobalInitiates Coverage OnBuy

View More Analyst Ratings for NKTR
View the Latest Analyst Ratings

Posted-In: Analyst Color Exclusives Analyst Ratings Movers Trading Ideas

 

Related Articles (NKTR)

The Cloud Rains Opportunity For Alibaba; Wells Fargo Projects 21% Upside In Shares

Musk Raises His Stake In Tesla, Bets Another $25 Million